Gert L. Perlhagen Net Worth

The estimated Net Worth of Gert L. Perlhagen is at least 108 百万$ dollars as of 14 March 2017. Gert Perlhagen owns over 125,000 units of NovoCure Ltd stock worth over 105,533,750$ and over the last 9 years Gert sold NVCR stock worth over 2,503,331$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gert Perlhagen NVCR stock SEC Form 4 insiders trading

Gert has made over 3 trades of the NovoCure Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently Gert bought 125,000 units of NVCR stock worth 866,250$ on 14 March 2017.

The largest trade Gert's ever made was selling 676,576 units of NovoCure Ltd stock on 5 August 2016 worth over 1,251,666$. On average, Gert trades about 211,165 units every 32 days since 2016. As of 14 March 2017 Gert still owns at least 6,125,000 units of NovoCure Ltd stock.

You can see the complete history of Gert Perlhagen stock trades at the bottom of the page.

What's Gert Perlhagen's mailing address?

Gert's mailing address filed with the SEC is C/O NOVOCURE INC., 20 VALLEY STREAM PKWY, SUITE 300, MALVERN, PA, 19355.

Insiders trading at NovoCure Ltd

Over the last 9 years, insiders at NovoCure Ltd have traded over 237,132,855$ worth of NovoCure Ltd stock and bought 164,174 units worth 2,198,429$ . The most active insiders traders include Asaf Danziger、William Fwfd Ventures Fund ...、Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of 853,350$. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth 13,856$.

What does NovoCure Ltd do?

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Complete history of Gert Perlhagen stock trades at NovoCure Ltd

NovoCure Ltd executives and stock owners

NovoCure Ltd executives and other stock owners filed with the SEC include:

• William Doyle,
  Executive Chairman of the Board
• Asaf Danziger,
  President, Chief Executive Officer, Director
• Michael Ambrogi,
  Vice President - Senior Technology Fellow
• Wilhelmus Groenhuysen,
  Chief Operating Officer
• Pritesh Shah,
  Chief Commercial Officer
• Asaf Danziger,
  Pres, CEO & Director
• William F. Doyle,
  Exec. Chairman
• Wilhelmus C. M. Groenhuysen,
  Chief Operating Officer
• Todd C. Longsworth,
  Gen. Counsel
• Ashley Cordova,
  CFO & VP of Investor Relations
• Pritesh Shah,
  Chief Commercial Officer
• William Vernon,
  Lead Independent Director
• Jeryl Hilleman,
  Independent Director
• Martin Madden,
  Independent Director
• Sherilyn McCoy,
  Independent Director
• David Hung,
  Independent Director
• Kinyip Gabriel Leung,
  Independent Director
• Frank Leonard,
  Chief Development Officer
• Todd Longsworth,
  General Counsel
• Ely Benaim,
  Chief Medical Officer
• Ashley Cordova,
  Chief Financial Officer
• Dr. Ely Benaim M.D.,
  Chief Medical Officer
• Barak Ben Arye,
  Gen. Counsel
• Ingrid Goldberg,
  VP of Investor Relations
• Prof. Yoram Palti M.D., Ph.D.,
  Founder & CTO
• Uri Weinberg M.D., Ph.D.,
  Chief Science Officer
• Dr. Ely Benaim,
  Chief Medical Officer
• William Patrick Burke,
  Chief HR Officer
• Prof. Yoram Palti,
  Founder & CTO
• Timothy J Scannell,
  
• Eilon D. Kirson,
  Chief Scientific Officer
• Gert L.Volati Ltd Perlhagen,
  
• Peter M. Melnyk,
  Chief Commercial Officer
• Yoram Palti,
  Chief Technology Officer
• Charles G Iii Phillips,
  Director
• Louis J Jr Lavigne,
  Director
• Ltd Volati,
  10% owner
• William Fwfd Ventures Fund ...,
  
• Gert L. Perlhagen,
  Director
• William T. Burkoth,
  Director
• Capital Vii, L.P.Pomona Cap...,
  
• Moshe Giladi,
  Chief Science Officer
• Nicolas Leupin,
  Chief Medical Officer
• Robert J Jr Mylod,
  Director
• Timothy J. Langloss,
  Director
• Hansjoerg Wyss,
  10% owner
• Allyson J Ocean,
  
• William Patrick Burke,
  Chief Human Resources Officer
• Uri Weinberg,
  Chief Innovation Officer
• W Anthony Vernon,
  
• Kristin Stafford,
  
• Gabriel Leung,
  
• Arye Barak Ben,
  General Counsel
• Michal Nath Puri,
  Chief Human Resources Officer